As I was writing this article (Feb 27, ~5:45 AM EST), I reached out to him for clarification either to provide an updated or corrected comment, or to point me toward data I may be overlooking (which is entirely possible)
Abbreviations c.p.: Commercially pure GAG: Glycosaminoglycan GBR: Guided bone regeneration ISQ: Implant stability quotient OSI: Osseointegration speed index PRP: Platelet-rich plasma RFA: Resonance frequency analysis ROS: Reactive oxygen species SEM: Scanning electron microscopy UV: Ultraviolet VUV: Vacuum ultraviolet XPS: X-ray photoelectron spectroscopy References Berglundh T, Armitage G, Araujo MG, Avila-Ortiz G, Blanco J, Camargo PM, Chen S, Cochran D, Derks J, Figuero E, Hammerle CHF, Heitz-Mayfield LJA, Huynh-Ba G, Iacono V, Koo KT, Lambert F, McCauley L, Quirynen M, Renvert S, Salvi GE, Schwarz F, Tarnow D, Tomasi C, Wang HL, Zitzmann N
Nutrition matters too
Evolving Peptide Therapy: Safety and Evidence First As peptide therapy continues to evolve, the focus remains on: Safety: Understanding short- and long-term risk profiles Regulatory compliance: Using peptides that fit within current FDA and compounding regulations Scientific support: Prioritizing treatments backed by clinical data, not just anecdotal reports Individualization: Matching each patients treatment plan to their medical history, goals, and risk tolerance Potential Alternatives to Ipamorelin and CJC-1295: Tesamorelin and Hexarelin Tesamorelin and Hexarelin illustrate how newer or alternative peptides can help fill the gap left by Ipamorelin and CJC-1295
Semaglutide works by slowing stomach emptying and signaling fullness to your brainbut timing your injection can affect how well these mechanisms work
